We could support that CRP is a sensitive marker that has been shown to increase in response to malignancies [19, 26] such as lymphoma [18, 52], multiple myeloma [53], pancreatic cancer [54], and SCC [55]both in humans and dogs. This evidence concerns the gene CRP and pancreatic neoplasm.